

EFPIA DISCLOSURE HUNGARY 2020 - SCHEDULE													
Published on behalf of Bristol-Myers Squibb (Hungary)													
	Full Name <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered <i>(Art. 3)</i>	Country of Principal Practice <i>(Schedule 1)</i>	Principal Practice Address <i>(Art. 3)</i>	Unique country identifier <i>OPTIONAL</i> <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b & 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c & 3.01.2.c)</i>		TOTAL (without VAT)	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP												
						N/A	N/A					-	
	OTHER, NOT INCLUDED ABOVE												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						0	0	0	0	420,000	0	420,000
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>												3
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>												100%	
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO												
	Balikkó és Társaság egészségügyi szolgáltató és oktató Bt.	Pécs	Hungary	Felsővárház u. 65.	HU	0	0	0	0	210,000	0	210,000	
	Magyar Tüdőgyógyász Társaság	Budapest	Hungary	Frankel Leó u. 88.	HU	0	0	0	0	532,000	0	532,000	
	OTHER, NOT INCLUDED ABOVE												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						0	-	0	0	570,000	0	570,000
Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>												3	
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>												60%	
R & D	AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1										0	0	